



Academic Rheumatology  
Clinical Sciences Building  
City Hospital  
Nottingham  
NG5 1PB, UK

Tel: +44 (0) 115 8231756  
Fax: +44 (0) 115 8231756  
joanna.ramowski@nottingham.ac.uk

Ref: MED/1203

7 August 2013

Sophie Warner  
39A Leopold Street  
Loughborough  
Leicestershire  
LE11 5DL

Dear Sophie

### **Postgraduate Studentship at the University of Nottingham**

Congratulations! I am pleased to inform you that you have been allocated a Postgraduate Studentship at The University of Nottingham.

|  |  |
|--|--|
| <b>Type:</b>                               | Research PhD Studentship   |
| <b>Supervisor/School:</b>                  | Dr A Valdes and Prof M Doherty, School of Medicine   |
| <b>Project/Course Title:</b>               | Genetics and Epigenetics of Osteoarthritis   |
| <b>Funding Period:</b>                     | 3 years full time  |
| <b>Value of Award:</b>                     | Fees plus stipend  |
| <b>Stipend:</b>                            | £13,726 (2013-14) (this sum will increase annually in line with the EPSRC national minimum stipend rate) |
| <b>Other Allowances as itemised below:</b> |  |
| <b>Fees:</b>                               | Your award also covers the cost of standard HEU tuition fees to the University of Nottingham             |

The terms and conditions under which you are offered this studentship are set out in the University of Nottingham Quality Manual and The University of Nottingham Guide To The Terms and Conditions for Funding a Postgraduate Student. Any additional conditions relating to other funding schemes from which you have been offered sponsorship are given below.

Additional Terms:

Any other conditions will be outlined in your formal PhD offer from the University of Nottingham

The University requires students to assign to the University upon request the ownership of commercially exploitable intellectual property generated in the course of their studies or with the use of University facilities, subject to any third party rights and the provision of appropriate revenue sharing arrangements.

If you wish to accept this Award, please return the enclosed Letter of Acceptance to the School Office which will be taken as acceptance of the award on the terms and conditions stated. If you are unable to take up this award, it is important that you notify the School Office whose address is at the top of this letter, so that another student may be offered the place. In this event, please return the enclosed Notification of Withdrawal.

Stipend payments will be paid monthly by BACS (automated payments into your bank account). Please complete the account details requested on the Letter of Acceptance form. No payments will be made until you have completed the Registration process.

**The above details confirm the studentship funding offer. We also need you to complete an application form in order for you to receive your formal offer from the University to study for a PhD. In this connection would you please fully complete an application form on line available at <http://pgapps.nottingham.ac.uk>. You do not need to activate the request for references as this will be done by our office. If you have any questions about the online application system then please do not hesitate to contact me. If you could complete an on line application as soon as possible that would be appreciated.**

Many congratulations. We look forward to you studying with us.

Yours sincerely

Professor Michael Doherty  
Head of Department

Encs: Further Information  
Notification of Acceptance/Decline  
Guide To The Terms & Conditions For Funding of Postgraduate Research at The University of Nottingham.

For Tuition Fees use only

***(Note for Schools - any percentage not accounted for below will be billed direct to the student)***

| Sponsor breakdown | % Allocation |
|-------------------|--------------|
| Project Code      |              |
| Project Code      |              |
| Project Code      |              |

## Further Information

### 1. Value of Award

The value of your award is based on information given in the enclosed letter. Any material changes to your circumstances which might affect the value of your award should be notified to the School in which you are studying as soon as possible. If your award letter states that the stipend you have been awarded will increase in line with national minimum rates, your stipend payments will be increased automatically each year.

Tuition fees will be billed direct to the funding organisation that is paying your fees. You will not be billed directly unless the school has notified Nottingham University Tuition Fees department that you are responsible personally for all or part of your fees.

### 2. Termination

If an award is terminated prematurely, entitlement to payments ends on the date on which training finished. Students must understand that the University of Nottingham will recover any payments made in advance for a period beyond the termination date of the award.

---

# Research Grant Agreement

# eular

Pain call

---

## PROJECT TITLE:

**Functional genetic variants and molecular mechanisms for pain in knee osteoarthritis**

The European League Against Rheumatism ("EULAR")  
Seestrasse 240  
8802 Kilchberg  
Switzerland

of the **one part**,

and

## **The University of Nottingham**

University Park, Nottingham, NG7 2RD, United Kingdom

of the **other part**

**HAVE AGREED** to the following terms and conditions regarding the research project mentioned above and described in the proposed original Research document (Appendix 1), which forms an integral part of this grant agreement.

### **1. Scope of Work**

EULAR grants to UNIVERSITY ("Beneficiary") and Beneficiary accepts support for research investigations under the direction of Dr. Ana M Valdes at The University off Nottingham as described in Appendix 1 (Research).

### **2. Grant Payment**

In consideration of Beneficiary's exerting its good faith efforts to carry out the Research EULAR will pay Beneficiary a total grant amount of maximum:

EUR 144,757

EULAR will pay the total amount in yearly periods according to the budget provided in the Research proposal (Appendix 1). The yearly payment schedule is as follows:

- 50% of annual budget as pre-financing at the beginning of the year

- Remainder of the annual budget at the end of the year upon receipt of a detailed expense statement as well as a scientific progress report

Payments shall be transferred to an account to be named by Beneficiary.

### **3. Period of Performance**

Research under this Agreement will be performed during the period of 36 months, starting on 4<sup>th</sup> February 2013 (Start Date).

### **4. Principal Investigator**

Beneficiary's Principal Investigator shall be Dr. Ana M Valdes who shall be responsible for the direction and conduct of the Research and the diligent management of the funding provided hereunder.

### **5. Reports**

The Principal Investigator shall report to EULAR with respect to the progress of the Research at least once per year. Within six months after the expiration of this Agreement, the Principal Investigator shall submit a summary report to EULAR as well as at least one publication related to the Research (cf. article 6). EULAR shall keep all such reports and all information obtained from Beneficiary confidential and only use them in accordance with this Agreement.

### **6. Publications**

Beneficiary will strive to publish the results and discoveries emanating from the Research and acknowledge EULAR in any such publication for the funding received hereunder.

### **7. Intellectual Property**

Research tools such as standardised questionnaires, etc. developed as part of the Research shall be freely available to the public without charge.

### **8. Governing Law**

This Agreement shall be governed by the laws of Switzerland, without reference to its conflict of laws principles; the exclusive place of jurisdiction being Zurich (Switzerland).

### **9. No Oral Modification**

No change, modification, extension, termination, or waiver of this Agreement, or any of the provisions herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the parties hereto.

### **10. Effective Date, Term and Termination**

This Agreement is effective (Effective Date) commencing on the date that it is executed by all the parties. In the event that all the parties do not execute this Agreement on the same date,

then this Agreement is effective commencing on the date that the last party executes this Agreement.

This Agreement shall expire 36 months after Start Date unless extended or sooner terminated in accordance with the provisions of this section.

In the event Beneficiary's Principal Investigator is unavailable or unable to continue direction of the Research for a period in excess of ninety (90) days, Beneficiary shall notify EULAR and may nominate a replacement; if Beneficiary does not nominate a replacement or if that replacement is unsatisfactory to EULAR, EULAR may terminate this Agreement upon thirty (30) days written notice.

If EULAR fails to meet any of its obligations under this Agreement and shall fail to remedy these failures within sixty (60) days after receipt of written notice thereof, Beneficiary shall have the option of terminating this Agreement upon written notice thereof. In the event Beneficiary fails to meet its obligations under this Agreement and shall fail to remedy these failures within sixty (60) days after receipt of written notice thereof, EULAR shall have the option of terminating this Agreement upon written notice.

Upon termination of this Agreement, EULAR shall reimburse Beneficiary for all reasonable expenses or irrevocable commitments incurred as of the date of notice of termination but not to exceed the total amount committed under this Agreement.

Termination or expiration of this Agreement for reasons other than an unremedied failure to meet the material obligations under this Agreement shall not affect the rights and obligations of the parties accrued prior to termination.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized officers or representatives.

**For UNIVERSITY**

Date: 7/1/2013

By: \_\_\_\_\_

Mr. Paul N Cartledge  
Head of Research Grants and Contracts


  
\_\_\_\_\_  
(Signature)

**For EULAR**

Date: 11 December 2012

By: \_\_\_\_\_

Heinz Marchesi  
Executive Director

  
\_\_\_\_\_  
(Signature)

Europäische Rheumaliga  
(EULAR)  
Seestrasse 240  
CH-8802 Kilchberg  
Schweiz

Re: MP/18769

22 September 2009

Dr DA Walsh  
Academic Rheumatology  
University of Nottingham  
Clinical Sciences Building  
City Hospital  
Hucknall Road  
Nottingham  
NG5 1PB

Dear Dr Walsh

**LETTER OF AWARD**

I am pleased to inform you that **arc** has awarded you a Centre Initiative at a total cost of £2,499,891.00 for 60 months entitled “**The Arthritis Research Campaign Pain Centre**”. The start date for this award is 1<sup>st</sup> October 2009 and the expiry date is 30<sup>th</sup> September 2014. Please inform us as soon as possible if there has been any alteration to these dates.

The full details of the financial support are enclosed along with the standard conditions of award and any special conditions or policy guidelines relevant to this grant; a separate copy has been sent to your administrative authority. The **grant holder's** and the **host institution's** agreement of these conditions should be signed and returned as soon as possible, since payment of invoices can be authorised only when we have received these documents.

As **arc** is a national charity, depending on public donations to ensure the continuance of research into arthritis and rheumatic disease, it is essential that our Press Office be kept informed of potential breakthroughs or work that has a direct patient benefit. Keeping the regional and national media up-to-date with any developments in arthritis research will ensure our profile is raised.

It also helps our fundraising effort to have **arc**-funded researchers speak at branch meetings and talk to the press about their work if requested. Grant-holders will be required to assist our Area Appeals Managers and Press Office in this vital work.

**Please ensure that the grant reference 18769 is quoted on all future correspondence to avoid delay.**

Please contact the Research and Education Department if you have any queries concerning this award, and may I take this opportunity to wish you every success.

Yours sincerely

**Mr Michael Patnick**  
**Head of Research & Education Funding**

Cc Professor Weiya Zhang  
Dr Sara Kelly  
Professor Nadina Lincoln  
Miss Brigitte Scammell  
Professor Dorothee Auer  
Professor Michael Doherty  
Dr Victoria chapman

Ms Pauline Taylor

8th October 2014

Professor David Walsh  
Academic Rheumatology  
University of Nottingham  
Clinical Sciences Building  
City Hospital  
Hucknall Road  
Nottingham  
United Kingdom (England)  
NG5 1PB

Dear Professor Walsh

**LETTER OF AWARD**

I am pleased to inform you that Arthritis Research UK has awarded you a Centre of Excellence award at a total cost of £1,998,603.00 for 60 months entitled “**Arthritis Research UK Pain Centre**”. The start date for this award is 22<sup>nd</sup> March 2015 and the expiry date is 21<sup>st</sup> March 2020.

I enclose full details of the financial support, the standard conditions of award and any special conditions or policy guidelines relevant to this grant; a separate copy has been sent to your administrative authority. The **grant holder's** and the **host institution's** agreement of these conditions should be signed and returned as soon as possible, since payment of invoices can be authorised only when we have received these documents.

In March 2010 we re-launched the fight against arthritis. One of the most obvious and visible examples of this was the change of our name to Arthritis Research UK and the vibrant new logo and look and feel that will help us to raise awareness and maximise the impact of everything we do. We have ambitious plans to grow as a charity and increase the amount of funds we make available to researchers. To help us in this it is essential that the grant holder and host institution when acknowledging Arthritis Research UK refer to the organisation by its full name, particularly in presentations and **do not abbreviate**.

As Arthritis Research UK is a national charity, depending on public donations to ensure the continuance of research into arthritis and rheumatic disease, it is essential that our Press Office be kept informed of potential breakthroughs or work that has a direct patient benefit. Keeping the regional and national media up-to-date with any developments in arthritis research will ensure our profile is raised.

It also helps our fundraising effort to have Arthritis Research UK funded researchers speak at branch meetings and talk to the press about their work if requested. Grant-holders will be required to assist our Area Appeals Managers and Press Office in this vital work.

**Patron** Her Royal Highness The Duchess of Cornwall

**Chesterfield Office** Copeman House, St Mary's Court, St Mary's Gate, Chesterfield, Derbyshire S41 7TD

**London Office** 41 Portland Place, London W1B 1QH

**Tel** 0300 790 0400 **Fax** 0300 790 0401 **www.arthritisresearchuk.org**

Registered Charity England and Wales No. 207711, Scotland No. SC041156. A Company registered in England and Wales and Limited by Guarantee No. 490500

**Please ensure that the grant reference 20777 is quoted on all future correspondence to avoid delay.**

Please contact the Research and Education Department if you have any queries concerning this award, and may I take this opportunity to wish you every success.

Yours sincerely



Dr Sarah Rudkin  
Head of Clinical Studies and Experimental Medicine

Cc Dr Sara Kelly  
Professor Michael Doherty  
Dr Weiya Zhang  
Professor Victoria Chapman  
Professor Brigitte Scammell  
Professor Dorothee Auer  
Professor Eamonn Ferguson  
Dr Ana Valdes  
Professor Kavita Vedhara

Miss Jenny Rowley